The War Over Cheaper Ozempic Won’t End Well for Some Investors
Wall Street Journal
Once Eli Lilly and Novo Nordisk increase the supply of weight-loss medications, companies such as Hims & Hers may find it trickier to sell compounded versions of the drugs.
https://www.wsj.com/articles/the-war-over-cheaper-ozempic-wont-end-well-for-some-investors-75b8acbf